
    
      After cardiac surgery under cardiopulmonary bypass (CPB) patients often show impairments of
      the immune system. Compared to placebo, CPB patients given alkaline phosphatase will have
      reduced composite endpoint of acute kidney injury, late extubation, gastrointestinal or
      neurological complications or death within 30 days.
    
  